Strides Pharma Science announced that its step]down wholly owned subsidiary, Strides Pharma Global, Singapore, has received approval for Triamcinolone Acetonide Ointment USP, 0.05% from the United States
Food & Drug Administration (USFDA). The product is part of the niche and small volume product portfolio with limited competition in the US market.
Triamcinolone Acetonide Ointment 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
According to IQVIA MAT data, the US market for Triamcinolone Acetonide Ointment USP, 0.05% is approximately US$ 15 Mn. The product will be manufactured at the companyfs flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
